IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 876-900 out of 1376.

<< < 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 > >>

Public Release: 8-Apr-2015
JAMA Dermatology
Melanoma surgery delays are common for Medicare patients
One in five Medicare patients with melanoma experience delays in getting surgery, a Yale study found.
Robert Wood Johnson Foundation, Yale Cancer Center/P30 Cancer Center Support Grant

Contact: Ziba Kashef
Yale University

Public Release: 8-Apr-2015
Genome Medicine
We may be looking at wrong mutation for breast cancer treatment
A leading gene candidate that has been the target of breast cancer drug development may not be as promising as initially thought, according to research published in open-access journal Genome Medicine.

Contact: Shane Canning
BioMed Central

Public Release: 8-Apr-2015
American Journal of Preventive Medicine
8 reasons the US Surgeon General should announce that UV tanning causes skin cancer
'In 1964 when the Surgeon General finally reported that smoking causes lung cancer, awareness and policy followed. Smoking rates declined and lung cancer rates have too. It's time for the Surgeon General to say the same thing about UV tanning,' says Robert P. Dellavalle, M.D., Ph.D., M.S.P.H., investigator at the CU Cancer Center.

Contact: Garth Sundem
University of Colorado Anschutz Medical Campus

Public Release: 8-Apr-2015
JAMA Dermatology
Delay of surgery for melanoma common among Medicare patients
In a study that included more than 32,000 cases of melanoma among Medicare patients, approximately one in five experienced a delay of surgery that was longer than 1.5 months, and about 8 percent of patients waited longer than three months for surgery, according to an article published online by JAMA Dermatology.

Contact: Ziba Kashef
The JAMA Network Journals

Public Release: 8-Apr-2015
JAMA Surgery
MRI screening program for individuals at high risk of pancreatic cancer
A magnetic resonance imaging (MRI)-based screening program for individuals at high risk of pancreatic cancer identified pancreatic lesions in 16 of 40 (40 percent) of patients, of whom five underwent surgery, according to a report published online by JAMA Surgery.

Contact: Marco Del Chiaro, M.D., Ph.D.
The JAMA Network Journals

Public Release: 7-Apr-2015
Annals of Behavioral Medicine
WSU study finds cigarette warning labels may be more effective with imagery
Young adults are more likely to appreciate the dangers of smoking when warnings are presented in images as well as text, according to a new study by a Washington State University Vancouver psychologist.
Washington State University

Contact: Renee Magnan
Washington State University

Public Release: 7-Apr-2015
Risk of breast and ovarian cancer may differ by type of BRCA1, BRCA2 mutation
Researchers have identified mutations that are associated with significantly different risks of breast and ovarian cancers. Authors say the results -- which show that some mutations confer higher risks of breast cancer, while other mutations show higher risks of ovarian cancer -- may lead to more effective cancer risk assessment, care and prevention strategies for health care providers and carriers. The results are published in the April 7 issue of JAMA.

Contact: Katie Delach
University of Pennsylvania School of Medicine

Public Release: 7-Apr-2015
Journal of Experimental Medicine
Central signaling pathway in lymphoma can be blocked successfully
Cancer researchers from the University of Zurich have identified a key signaling pathway in B-cell lymphoma, a malignant type of blood cancer. They demonstrate that the signaling pathway can be blocked using compounds that are already in clinical development. This finding might be extremely important for the diagnosis, prognosis and treatment of this disease in the future.

Contact: Anne Müller
University of Zurich

Public Release: 7-Apr-2015
Risk of breast and ovarian cancer may differ by type of BRCA1, BRCA2 mutation
In a study that involved more than 31,000 women who are carriers of disease-associated mutations in the BRCA1 or BRCA2 genes, researchers identified mutations that were associated with significantly different risks of breast and ovarian cancers, findings that may have implications for risk assessment and cancer prevention decision making among carriers of these mutations, according to a study in the April 7 issue of JAMA.

Contact: Katie Delach
The JAMA Network Journals

Public Release: 7-Apr-2015
Cancer Biology & Therapy
Physicians pioneer the use of stereotactic body radiation for deadly kidney cancer complication
UT Southwestern Medical Center Kidney Cancer Program investigators have published what is believed to be the first reported successful use of stereotactic body radiation therapy for an often deadly complication of kidney cancer.

Contact: Lori Sundeen Soderbergh
UT Southwestern Medical Center

Public Release: 7-Apr-2015
Human Genome Variation
A better biomarker to predict cetuximab response in CRC patients
Scientists at Insilico Medicine Inc. and Champions Oncology Inc. have successfully demonstrated a method to predict response to cetuximab in patients with colorectal cancer using OncoFinder pathway activation strength. The study identified a novel prognostic marker in colorectal cancer treated with cetuximab.

Contact: Qingsong Zhu
InSilico Medicine, Inc.

Public Release: 7-Apr-2015
Stem Cells
Moffitt researchers discover novel mechanism controlling lung cancer stem cell growth
Moffitt Cancer Center researchers discovered a novel mechanism that plays an important role in the maintenance of lung cancer stem cells. This finding may lead to new potential therapeutic targets.
National Institutes of Health

Contact: Kim Polacek
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 7-Apr-2015
Health Affairs
Cost of cancer drugs varies widely based on who's paying
Uninsured cancer patients are asked to pay anywhere from two to 43 times what Medicare would pay for chemotherapy drugs, according to a new study from the University of North Carolina at Chapel Hill.

Contact: Thania Benios
University of North Carolina at Chapel Hill

Public Release: 6-Apr-2015
Health Affairs
With breast cancer treatment, you do get what you pay for
Despite concerns about the increasing costs of treating illnesses like breast cancer, higher treatment costs are linked to better survival rates, according to a study by Yale School of Medicine researchers in the Cancer Outcomes Public Policy and Effectiveness Research Center at Yale School of Medicine and Yale Cancer Center.
Yale Office of Student Research

Contact: Karen N. Peart
Yale University

Public Release: 6-Apr-2015
Proceedings of the National Academy of Sciences
Study suggests new role for gene in suppressing cancer
Scientists at the University of Manchester have discovered that a previously known gene also helps cells divide normally and that its absence can cause tumors.

Contact: Jamie Brown
University of Manchester

Public Release: 6-Apr-2015
Developmental Cell
Origin of cancer wasting identified in fruit flies
The progressive wasting of muscle and fat tissue throughout the body is one of the most visible and heartbreaking manifestations of cancer, yet little is known about how tumors cause distant tissues to degenerate. Two studies published in Developmental Cell reveal that a tumor-secreted molecule drives the loss of fat and muscle tissue in fly cancer models that replicate key features of tumor-induced wasting in humans. The findings could lead to much-needed therapies for wasting.

Contact: Joseph Caputo
Cell Press

Public Release: 6-Apr-2015
Journal of Clinical Oncology
A third of breast cancer patients concerned about genetic risk
A new study from the University of Michigan Comprehensive Cancer Center finds that many women diagnosed with breast cancer are concerned about the genetic risk of developing other cancers themselves or of a loved one developing cancer.
NIH/National Cancer Institute, American Cancer Society

Contact: Nicole Fawcett
University of Michigan Health System

Public Release: 6-Apr-2015
Cancer drug target also essential for blood cell recovery
Blocking key 'survival' proteins is a promising tactic for treating cancer, however new research suggests care should be taken as these proteins are also vital for emergency blood cell production. Dr. Alex Delbridge, Dr. Stephanie Grabow, and professor Andreas Strasser from the Walter and Eliza Hall Institute discovered that blood cell production following massive blood cell depletion was fatally compromised when the cell survival protein MCL-1 was depleted.
Cancer Council Victoria, Lady Tata Memorial Trust, Leukemia and Lymphoma Society, Cancer Therapeutics CRC, National Health and Medical Research Council, Redstone Foundation, Victorian Government

Contact: Alan Gill
Walter and Eliza Hall Institute

Public Release: 6-Apr-2015
Molecular Cell
Common cancers hijack powerhouses of cells
In a breakthrough in the understanding of how cancer does its deadly work, researchers have shown that many cancers -- including nearly all pancreatic cancers -- enslave and deform mitochondria, the powerhouses of cells, to create an environment more conducive to tumor growth.
American Cancer Society

Contact: Josh Barney
University of Virginia Health System

Public Release: 6-Apr-2015
Cancer Epidemiology, Biomarkers & Prevention
Childhood cancer survivors face chronic health problems
Childhood cancer survivors have increased, but the majority of those who have survived face chronic health problems, diseases and disability related to treatment, reports a new study. The study is the first to estimate the national prevalence of treatment-related chronic disease among survivors of childhood cancer. Simply curing cancer is no longer enough, scientists said.
National Institutes of Health

Contact: Marla Paul
Northwestern University

Public Release: 6-Apr-2015
Cancer Biotherapy and Radiopharmaceuticals
Can cancer vaccines prolong survival?
Therapeutic anti-cancer vaccines developed to treat metastatic disease such as advanced prostate cancer or melanoma rarely have a noticeable effect on the tumor but have been associated with a statistically significant increase in patient survival. Robert O. Dillman, M.D., NeoStem Inc., asserts that 'overall survival' rather than 'progression-free survival' should be the gold standard for evaluating the efficacy of cancer vaccines in clinical trials, in a provocative new article published in Cancer Biotherapy and Radiopharmaceuticals.

Contact: Kathryn Ryan
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 6-Apr-2015
International Journal of Radiation Oncology • Biology • Physics
Erythropoietin combined with radiation therapy does not improve local-regional control in anemic patients with head and neck cancer
Long-term analysis of Radiation Therapy Oncology Group 9903 demonstrates that the addition of erythropoietin did not improve local-regional control for anemic patients with head and neck squamous cell carcinoma who receive radiation therapy or chemoradiation, according to a study published in the April 1, 2015 issue of the International Journal of Radiation Oncology * Biology * Physics.

Contact: Michelle Kirkwood
American Society for Radiation Oncology

Public Release: 6-Apr-2015
New target for anticancer drugs: RNA
Messenger RNAs -- the working copies of genes that are used to assemble proteins -- have typically been ignored as drug targets because they all look about the same. But UC Berkeley researchers have found that a subset of mRNAs -- many of which have been linked to cancer -- have unique tags. These short RNA tags bind to a protein, eIF3, that regulates translation at the ribosome, making the binding site a promising target for anticancer drugs.
NIH/National Institute of General Medical Sciences

Contact: Robert Sanders
University of California - Berkeley

Public Release: 6-Apr-2015
Proceedings of the National Academy of Sciences
Device extracts rare tumor cells using sound
A simple blood test may one day replace invasive biopsies thanks to a new device that uses sound waves to separate blood-borne cancer cells from white blood cells. Carnegie Mellon University President Subra Suresh and fellow researchers from the Massachusetts Institute of Technology and The Pennsylvania State University report the latest advancement that brings their device one step closer to clinical use in a paper published this week in the online early edition of the Proceedings of the National Academy of Sciences.
National Institutes of Health, Penn State Center for Nano Scale Science, National Science Foundation

Contact: Jocelyn Duffy
Carnegie Mellon University

Public Release: 5-Apr-2015
Nano Research
MIPT researchers put safety of magic anti-cancer bullet to test
A group of MIPT researchers together with their colleagues from Moscow, Nizhny Novgorod, Australia and the Netherlands have carried out the first systematic study analyzing the safety of so-called upconversion nanoparticles that may be used to treat skin cancer and other skin diseases. This study is one of the most important steps on the path to new, safe and effective methods to diagnose and treat cancer.

Contact: Stanislav Goryachev
Moscow Institute of Physics and Technology

Showing releases 876-900 out of 1376.

<< < 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 > >>

  Search News Releases